Have a personal or library account? Click to login
Casirivimab and imdevimab as investigational monoclonal antibodies for COVID-19 patients – review of the literature Cover

Casirivimab and imdevimab as investigational monoclonal antibodies for COVID-19 patients – review of the literature

Current Issues in Pharmacy and Medical Sciences
Volume 34 (2021): Issue 3 (September 2021)
By: Gabriela Reka,  Angelika Pawlak,  Piotr Machowiec,  Marcela Maksymowicz and  Halina Piecewicz-Szczesna  
Open Access
|Oct 2021
DOI: https://doi.org/10.2478/cipms-2021-0030 | Journal eISSN: 2300-6676 | Journal ISSN: 2084-980X
Journal RSS Feed
Language: English
Page range: 138 - 141
Submitted on: Mar 29, 2021
|
Accepted on: Aug 20, 2021
|
Published on: Oct 8, 2021
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
COVID-19,
REGN-COV-2,
casirivimab,
imdevimab,
monoclonal antibodies
Related subjects:
Medicine,
Clinical medicine,
Clinical medicine, other,
Pharmacology, toxicology,
Pharmacy,
Pharmacy, other

© 2021 Gabriela Reka, Angelika Pawlak, Piotr Machowiec, Marcela Maksymowicz, Halina Piecewicz-Szczesna, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 34 (2021): Issue 3 (September 2021)Next article